← Leaderboards
Jeffrey B. Travers
Dayton Va Medical Center
$11,981,540
Attributed
$17,049,351
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,049,351 · 10
VA$0 · 4
By mechanism
R01$13,529,705 · 4
U19$1,276,033 · 1
RF1$877,297 · 1
R34$675,000 · 1
R21$358,160 · 1
K08$201,749 · 1
Top collaborators
- Dan F Spandau14 shared
- Raymond L Konger5 shared
- Yanfang Chen3 shared
- Ravi Prakash Sahu3 shared
- Michael George Kemp2 shared
- Courtney E Sulentic2 shared
- Craig Rohan1 shared
Most similar at Dayton Va Medical Center
Same institution · by research overlap
- Michael George Kemp$1,815,500
- Craig Rohan$0
Others in their field
Top investigators on “Keratinocyte”
- David Heimbrook · Leidos Biomedical Research, Inc.$31,285,017
- Kathleen Janee Green · Northwestern University$26,824,381
- Elaine Fuchs · University Of Chicago$24,033,644
- Gian Paolo Dotto · Massachusetts General Hospital$19,822,465
- Richard L Gallo · University Of California, San Diego$19,668,478
- Pierre Coulombe · Johns Hopkins University$19,316,020
Research focus
KeratinocyteSkinIn VitroUltraviolet B RadiationMediatingIn VivoProductionResponseDesignPlatelet Activating FactorCytokineAcuteSkin CancerMorbidity - Disease RatePathway InteractionsLipid MediatorPlatelet Activating Factor ReceptorAgonistLaboratoriesNeoplasmsReceptor SignalingSkin CarcinomaCellsEnzymes
Grant awards (76)
Wounding Therapy and Photocarcinogenesis$877,297
RF1 · FY2025 · AG · contact PI
UVB radiation-generated microvesicle particles as effectors for photosensitivity$337,500
R01 · FY2025 · ES · contact PI
Oxidized lipids and microvesicle particles as effectors for chemical threats to skin$225,000
R34 · FY2025 · AR · contact PI
Acid Sphingomyelinase Inhibition to Mitigate the Environmental Exposure Risks of Ultraviolet Light-Induced Actinic Neoplasia and Squamous Cell Carcinoma in US Veterans$0
I01 · FY2025 · VA · contact PI
Oxidized Lipids and UV Immunosuppression$0
I01 · FY2025 · VA · contact PI
Wounding Therapy and Photocarcinogenesis$449,417
R01 · FY2024 · AG · contact PI
UVB radiation-generated microvesicle particles as effectors for photosensitivity$337,500
R01 · FY2024 · ES · contact PI
Oxidized lipids and microvesicle particles as effectors for chemical threats to skin$262,500
R34 · FY2024 · AR · contact PI
Oxidized Lipids and UV Immunosuppression$0
I01 · FY2024 · VA · contact PI
Wounding Therapy and Photocarcinogenesis$450,670
R01 · FY2023 · AG · contact PI
Platelet Activating Factor and Epidermal Cytoxicity$375,000
R01 · FY2023 · HL · contact PI
UVB radiation-generated microvesicle particles as effectors for photosensitivity$337,500
R01 · FY2023 · ES · contact PI
Oxidized lipids and microvesicle particles as effectors for chemical threats to skin$187,500
R34 · FY2023 · AR · contact PI
Oxidized Lipids and UV Immunosuppression$0
I01 · FY2023 · VA · contact PI
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response$0
I01 · FY2023 · VA · contact PI
Wounding Therapy and Photocarcinogenesis$472,255
R01 · FY2022 · AG · contact PI
Platelet Activating Factor and Epidermal Cytoxicity$375,000
R01 · FY2022 · HL · contact PI
UVB radiation-generated microvesicle particles as effectors for photosensitivity$337,500
R01 · FY2022 · ES · contact PI
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response$0
I01 · FY2022 · VA · contact PI
Oxidized Lipids and UV Immunosuppression$0
I01 · FY2022 · VA · contact PI
Platelet Activating Factor and Epidermal Cytoxicity$375,000
R01 · FY2021 · HL · contact PI
UVB radiation-generated microvesicle particles as effectors for photosensitivity$337,500
R01 · FY2021 · ES · contact PI
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response$0
I01 · FY2021 · VA · contact PI
Oxidized Lipids and UV Immunosuppression$0
I01 · FY2021 · VA · contact PI
Platelet Activating Factor and Epidermal Cytoxicity$375,000
R01 · FY2020 · HL · contact PI
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response$0
I01 · FY2020 · VA · contact PI
Oxidized lipids and UV immunosuppression$0
I01 · FY2019 · VA · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$374,675
R01 · FY2018 · HL · contact PI
Wounding therapy and photocarcinogenesis$308,969
R01 · FY2018 · AG · contact PI
Oxidized lipids and UV immunosuppression$0
I01 · FY2018 · VA · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$374,540
R01 · FY2017 · HL · contact PI
Wounding therapy and photocarcinogenesis$308,933
R01 · FY2017 · AG · contact PI
Photodynamic Therapy-Induced Immune Modulation: Mechanisms and Influence on Therapeutic Efficacy$162,800
R21 · FY2017 · AR · contact PI
Oxidized lipids and UV immunosuppression$0
I01 · FY2017 · VA · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$373,713
R01 · FY2016 · HL · contact PI
Mechanisms of photocarcinogenesis in geriatric skin$351,000
R01 · FY2016 · ES
Wounding therapy and photocarcinogenesis$308,919
R01 · FY2016 · AG · contact PI
Photodynamic Therapy-Induced Immune Modulation: Mechanisms and Influence on Therapeutic Efficacy$195,360
R21 · FY2016 · AR · contact PI
Oxidized lipids and UV immunosuppression$0
I01 · FY2016 · VA · contact PI
IGF-1 and the initiation of non-melanoma skin cancer$0
I01 · FY2016 · VA · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$385,606
R01 · FY2015 · HL · contact PI
Mechanisms of photocarcinogenesis in geriatric skin$345,960
R01 · FY2015 · ES
Wounding therapy and photocarcinogenesis$310,206
R01 · FY2015 · AG · contact PI
IGF-1 and the initiation of non-melanoma skin cancer$0
I01 · FY2015 · VA · contact PI
IGF-1 and the initiation of non-melanoma skin cancer$0
I01 · FY2015 · VA · contact PI
Oxidized lipids and UV immunosuppression$0
I01 · FY2015 · VA · contact PI
Mechanisms of photocarcinogenesis in geriatric skin$337,510
R01 · FY2014 · ES
Wounding therapy and photocarcinogenesis$319,800
R01 · FY2014 · AG · contact PI
Oxidized lipids and UV immunosuppression$0
I01 · FY2014 · VA · contact PI
IGF-1 and the initiation of non-melanoma skin cancer$0
I01 · FY2014 · VA · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$362,855
R01 · FY2013 · HL · contact PI
Mechanisms of photocarcinogenesis in geriatric skin$334,102
R01 · FY2013 · ES
The Indiana Cutaneous Biological Research Training Program$131,407
T32 · FY2013 · AR · contact PI
Oxidized lipids and UV immunosuppression$0
I01 · FY2013 · VA · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$381,150
R01 · FY2012 · HL · contact PI
Mechanisms of photocarcinogenesis in geriatric skin$340,920
R01 · FY2012 · ES
Oxidized lipids and UV immunosuppression$0
I01 · FY2012 · VA · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$385,000
R01 · FY2011 · HL · contact PI
Oxidized lipids and UV immunosuppression$0
I01 · FY2011 · VA · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$385,000
R01 · FY2010 · HL · contact PI
Bacterial Products as Potentiaters of Atopic Dermatitis (AD)$269,751
U19 · FY2010 · AI · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$385,000
R01 · FY2009 · HL · contact PI
Bacterial Products as Potentiaters of Atopic Dermatitis (AD)$264,539
U19 · FY2009 · AI · contact PI
Bacterial Products as Potentiaters of Atopic Dermatitis (AD)$256,838
U19 · FY2008 · AI · contact PI
Platelet Activating Factor and Epidermic Cytotoxicity$285,402
R01 · FY2007 · HL · contact PI
Bacterial Products as Potentiaters of Atopic Dermatitis (AD)$250,797
U19 · FY2007 · AI · contact PI
Platelet Activating Factor and Epidermic Cytotoxicity$293,927
R01 · FY2006 · HL · contact PI
Bacterial Products as Potentiaters of AD$234,108
U19 · FY2006 · AI · contact PI
Platelet Activating Factor and Epidermic Cytotoxicity$301,000
R01 · FY2005 · HL
Platelet Activating Factor and Epidermic Cytotoxicity$301,000
R01 · FY2004 · HL
Platelet Activating Factor and Epidermic Cytotoxicity$301,000
R01 · FY2003 · HL
PLATELET ACTIVATING FACTOR AND EPIDERMAL CYTOTOXICITY$309,840
R01 · FY2002 · HL
PLATELET ACTIVATING FACTOR AND EPIDERMAL CYTOTOXICITY$251,784
R01 · FY2001 · HL
PLATELET ACTIVATING FACTOR IN KERATINOCYTE FUNCTION$102,046
K08 · FY2001 · AR
PLATELET ACTIVATING FACTOR AND EPIDERMAL CYTOTOXICITY$252,052
R01 · FY2000 · HL
PLATELET ACTIVATING FACTOR IN KERATINOCYTE FUNCTION$99,703
K08 · FY2000 · AR